Business Description
Nexalis Therapeutics Ltd
ISIN : AU0000456733
Description
Nexalis Therapeutics Ltd is an Australian clinical-stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression (SRX-25), breakthrough cancer pain (IRX-211), and panic disorder (IRX-616a), each addressing areas of unmet medical need and potential commercial demand.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.59 | |||||
Equity-to-Asset | -0.97 | |||||
Debt-to-Equity | -0.63 | |||||
Debt-to-EBITDA | -0.5 | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 14 | |||||
3-Year EPS without NRI Growth Rate | 10.1 | |||||
3-Year FCF Growth Rate | 28.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 27.06 | |||||
9-Day RSI | 30.64 | |||||
14-Day RSI | 32.63 | |||||
3-1 Month Momentum % | -15.79 | |||||
6-1 Month Momentum % | -27.27 | |||||
12-1 Month Momentum % | -59.71 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.58 | |||||
Quick Ratio | 0.58 | |||||
Cash Ratio | 0.21 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.3 | |||||
Shareholder Yield % | -33.16 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROA % | -144.64 | |||||
ROIC % | -1364.34 | |||||
3-Year ROIIC % | -196.97 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
EV-to-EBIT | -1.91 | |||||
EV-to-EBITDA | -1.91 | |||||
EV-to-FCF | -3.19 | |||||
Earnings Yield (Greenblatt) % | -52.36 | |||||
FCF Yield % | -35.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nexalis Therapeutics Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil A$) | |||
| EPS (TTM) (A$) | -0.008 | ||
| Beta | 0.7074 | ||
| 3-Year Sharpe Ratio | -0.03 | ||
| 3-Year Sortino Ratio | -0.05 | ||
| Volatility % | 69.17 | ||
| 14-Day RSI | 32.63 | ||
| 14-Day ATR (A$) | 0.00094 | ||
| 20-Day SMA (A$) | 0.01195 | ||
| 12-1 Month Momentum % | -59.71 | ||
| 52-Week Range (A$) | 0.01 - 0.044673 | ||
| Shares Outstanding (Mil) | 253.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nexalis Therapeutics Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nexalis Therapeutics Ltd Stock Events
| Event | Date | Price (A$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nexalis Therapeutics Ltd Frequently Asked Questions
What is Nexalis Therapeutics Ltd(ASX:NX1)'s stock price today?
The current price of ASX:NX1 is A$0.01. The 52 week high of ASX:NX1 is A$0.04 and 52 week low is A$0.01.
When is next earnings date of Nexalis Therapeutics Ltd(ASX:NX1)?
The next earnings date of Nexalis Therapeutics Ltd(ASX:NX1) is .
Does Nexalis Therapeutics Ltd(ASX:NX1) pay dividends? If so, how much?
Nexalis Therapeutics Ltd(ASX:NX1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Nexalis Therapeutics Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers